Medical Devices - Robotic Surgical Systems / Urology
Strategic Profile
The company's Aquablation therapy is designed to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) independent of prostate size and shape or surgeon experience. With current Aquablation market penetration at approximately 10% of the treated market where roughly 400,000 patients per year undergo prostate procedures, PROCEPT has substantial headroom for growth from millions of men on drug therapy.
Cyborg Score Rationale
The company projects strong 2026 financial performance with $390-$410 million in revenue (27-33% growth), 60,000-64,000 procedures, 65% gross margin, and adjusted EBITDA losses narrowing to $30-$17 million with positive EBITDA expected in Q4. Strategic focus on procedure-driven growth and a clear path to profitability in 2027 demonstrates operational maturity and market leadership positioning.
Top Insights
Record Q4 2025 performance with approximately 12,200 procedures and 65 new system sales marking the company's strongest capital quarter
Pricing discipline improvements with handpiece average selling prices expected to rise to approximately $3,500 in 2026 through elimination of quarter-end discounts
WATER IV prostate cancer clinical trial procedures expected to be completed by mid-2026 significantly faster than anticipated, positioning potential market expansion beyond BPH
Business mix shift: systems represented over 50% of revenue in 2021 but expected to be less than 25% in 2026, with disposables/procedures driving larger share and margin expansion
Named Competitors
da Vinci Surgical System — General-purpose robotic surgery platform used across multiple surgical specialties including urology
Traditional Surgical Approaches — TURP and open prostatectomy procedures for BPH treatment
Laser-based Treatments — Laser prostate ablation procedures for BPH
Recent Developments
(February 2026) Hosted 2026 Investor Day outlining multi-year growth strategy with $390-$410M revenue guidance for 2026
(February 2026) Q4 2025 record procedure volume of ~12,200 procedures and 65 new system sales
(February 2026) Updated WATER IV prostate cancer trial timeline to complete procedures by mid-2026
Open the full interactive PROCEPT BioRobotics Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.